Extinction of fear is thought to use similar learning mechanisms as learning or conditioning of fear, and both are blocked by antagonists at the glutamatergic N-methyl-D-aspartate (NMDA) receptor. Futhermore, agonists at this site appear to augment some forms of learning in animal and human trials. The process of extinction of conditioned fear has recently been shown to be facilitated by D-Cycloserine (DCS), an NMDA agonist, given in individual doses prior to extinction training in an animal model. We have preliminary evidence that a similar effect is found in human subjects undergoing controlled exposure therapy for specific phobia. This translational research application represents a blinded, randomized, placebo-controlled efficacy study with the goal of determining whether a drug that acutely enhances learning in animal models will facilitate the extinction of fear that occurs with behavioral exposure therapy and whether a drug that has been shown to interfere with the extinction of fear will decrease the efficacy of exposure therapy. Specifically, it is proposed that a single dose of DCS, given shortly before each of 2 individual virtual reality exposure (VRE) therapy sessions, will significantly enhance the rate of response and possibly the efficacy of treatment, and that a single dose of alprazolam, a benzodiazepine, given shortly before each of 2 VRE therapy sessions, will significantly retard the long term efficacy of treatment. To this end, we propose to enroll 176 participants with the fear of public speaking to achieve 132 completers, or approximately 44 per group. Participants will be randomly assigned to receive VRE in combination with 50 mg DCS, placebo, or .5mg Alprazolam. Comprehensive multi-modal outcomes will be assessed by independent assessors blind to subject condition on interviews, self-report measures, psychophysiological measures, and a behavioral avoidance test consisting of an actual speech in front of a live audience. Participants will be assessed pre- and post-treatment and at follow-ups of 3 and 12 months to assess long-term effects. This type of combined treatment - specific pharmacotherapeutic augmentation of psychotherapy - would be novel and would potentially be generalizable to many different forms of psychotherapy for a wide range of disorders. If this translational research is successful, the ability of a relatively benign agent administered acutely before a psychotherapy session to facilitate the psychotherapeutic process could have important clinical, humanitarian, and economic advantages.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH070880-04
Application #
7684123
Study Section
Special Emphasis Panel (ZMH1-ERB-S (08))
Program Officer
Tuma, Farris K
Project Start
2005-09-30
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$452,072
Indirect Cost
Name
Emory University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Maples-Keller, Jessica L; Yasinski, Carly; Manjin, Nicole et al. (2017) Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress. Neurotherapeutics 14:554-563
Maples-Keller, Jessica L; Bunnell, Brian E; Kim, Sae-Jin et al. (2017) The Use of Virtual Reality Technology in the Treatment of Anxiety and Other Psychiatric Disorders. Harv Rev Psychiatry 25:103-113
Norrholm, Seth Davin; Jovanovic, Tanja; Gerardi, Maryrose et al. (2016) Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behav Res Ther 82:28-37
Price, Matthew; Maples, Jessica L; Jovanovic, Tanja et al. (2015) An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. Depress Anxiety 32:392-9
Rothbaum, Barbara Olasov; Price, Matthew; Jovanovic, Tanja et al. (2014) A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 171:640-8
Butelman, Eduardo R; Yuferov, Vadim; Kreek, Mary Jeanne (2012) ?-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35:587-96
Zoellner, Lori A; Rothbaum, Barbara O; Feeny, Norah C (2011) PTSD not an anxiety disorder? DSM committee proposal turns back the hands of time. Depress Anxiety 28:853-6
Jovanovic, Tanja; Norrholm, Seth D; Blanding, Nineequa Q et al. (2010) Fear potentiation is associated with hypothalamic-pituitary-adrenal axis function in PTSD. Psychoneuroendocrinology 35:846-57
Hasenkamp, Wendy; Norrholm, Seth D; Green, Amanda et al. (2008) Differences in startle reflex and prepulse inhibition in European-Americans and African-Americans. Psychophysiology 45:876-82
Gerardi, Maryrose; Rothbaum, Barbara Olasov; Ressler, Kerry et al. (2008) Virtual reality exposure therapy using a virtual Iraq: case report. J Trauma Stress 21:209-13